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This web page provides estimates on the burden of influenza and the impact of annual
influenza vaccination in the United States for the 2016–2017 influenza season.
For the past several years, CDC has used a model to estimate the numbers of influenza
illnesses, medical visits, hospitalizations, and the impact of influenza vaccination on these
numbers in the United States (1-5). The methods used to calculate the estimates have been
described previously (1,2) and are outlined briefly below. CDC uses the estimates of the
burden of influenza in the population and the impact of influenza vaccination to inform policy
and communications related to influenza.
2016–2017 Estimates
Influenza activity in the United States during the 2016–2017 season began to increase in
December and peaked in mid-February (6). While influenza A(H3N2) viruses predominated
through mid-March, and were predominant overall for the season, influenza B viruses were
more commonly reported from late March through May. The season was notable because of
high hospitalization rates, particularly among adults aged 50–64 years and ≥65 years. Overall
and for all ages, hospitalization rates were similar to the rates observed during the 2012–2013
and 2014–2015 seasons, both of which were influenza A(H3N2)-predominant seasons
characterized with “high” severity among older adults (7).
These high hospitalization rates equated with a substantial influenza burden of illness during
the 2016–2017 season with an estimated 30.9 million people getting sick with influenza, 14.5
million going to a health care provider for influenza, and an estimated 600,000 people being
hospitalized from influenza (see Table 1). Overall, the burden estimates for last season were
approximately as high as the estimated burden for 2012–2013 and 2014–2015 seasons (see
Figure 1 & Table 2).
The number and proportion of influenza-associated hospitalizations prevented by vaccination
during 2016–2017 varied by age group, due to age-specific diﬀerences in influenza burden,
vaccine coverage, and vaccine eﬀectiveness. Vaccination prevented the lowest proportion of
illnesses among adults aged 18 to 49 years, who had the lowest vaccine coverage, and
adults aged ≥65 years, who had higher vaccine coverage but the lowest vaccine
eﬀectiveness. Vaccination prevented the greatest proportion of outcomes among children
aged 6 months to 4 years and 5 to 17 years, where the burden of influenza illness and
medical visits was high and the vaccine eﬀectiveness was greatest.
How can we reduce influenza illness?
Improvements in vaccine coverage could provide a greater public health benefit. For
example, if vaccination rates increased by just 5 percentage points across the entire
population, another 483,000 illnesses, 232,000 medical visits, and 6,950 hospitalizations
associated with influenza could be prevented. If vaccination rates improved to the Healthy
People goal of 70% for all age groups, another 1.89 million illnesses, 822,000 medical visits,
and 17,300 hospitalizations could have been prevented during the 2016-2017 influenza
season.
Strategies to improve vaccine coverage include ensuring influenza vaccination status is
assessed at each heath care encounter during the influenza season (October through May),
ensuring patients receive a recommendation to get vaccinated and an oﬀer of vaccination
from their provider, using standing orders in the health care oﬃce, using patient
reminder/recall systems aided by immunization information systems, and expanding
vaccination access through use of nontraditional settings for vaccination (e.g., pharmacies,
workplaces, and schools) to reach persons who might not visit a physician’s oﬃce during the
influenza season.
Similarly, improvements to vaccine eﬀectiveness could provide incremental public health
benefit. Several eﬀorts are currently underway to understand and investigate factors that
contribute to reduced or increased vaccine eﬀectiveness and these are described further by
Flannery, et al. (9). In brief, higher vaccine eﬀectiveness may be seen with diﬀerent vaccine
production methods or formulations, including higher doses of antigen or the additional of
adjuvants to stimulate the immune response.
Conclusion
CDC estimates that influenza vaccination during the 2016–2017 influenza season prevented
an estimated 5.29 million illnesses, 2.64 million medical visits, and 84,700 hospitalizations
associated with influenza. This report underscores the benefits of the current vaccination
program, but also highlights areas where improvements in vaccine uptake and vaccine
eﬀectiveness could deliver even greater benefits to the public’s health. For example,
increasing vaccination coverage among working-age adults younger than 65 years would
further reduce the burden of influenza, as this age group continues to have the lowest
influenza vaccination coverage.
Limitations
These estimates are subject to several limitations. First, influenza vaccination coverage
estimates were derived from reports by survey respondents, not vaccination records, and are
subject to recall bias. These coverage estimates are based on telephone surveys with
relatively low response rates; nonresponse bias may remain after weighting for the survey
design. Estimates of the number of persons vaccinated based on these survey data have
often exceeded the actual number of doses distributed, indicating that coverage estimates
used in this report may overestimate the numbers of illnesses and hospitalizations averted by
vaccination. The model of averted illness calculates outcomes directly prevented among
persons who were vaccinated. If there is also indirect protection from decreased exposure to
infectious persons in a partially vaccinated population (i.e., herd immunity), the model would
underestimate the number of illnesses and hospitalizations prevented by vaccination.
Estimates of the averted burden in older adults, aged ≥65 years, do not reflect the increasing
use of high-dose or adjuvanted influenza vaccines, which may have higher eﬀectiveness
compared with standard vaccines; nor does the estimate reflect that vaccine eﬀectiveness
might continue to decrease with age, reaching very low levels among the oldest adults who
also have the highest rates of influenza vaccination. Finally, because the data and methods
used to make these calculations are continually updated, future estimates may diﬀer from
those presented here.
Previous Estimates
Previous estimates of the burden of illness, medical visits, and hospitalizations related to
influenza are available online and in scientific publications (1-5). Estimates using the same
methodology as for the 2016-2017 season are shown in the tables below to provide context
for the current season’s estimates.
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2016-2017 Tables for Influenza Burden and Burden-Averted Estimates
Age (yrs) Total population Estimated illnesses Estimated medical visits
No. 95% CI No.
<5 19,927,037 2,320,000 1,990,000-
2,780,000
1,560,000
5-17 53,715,248 6,150,000 5,330,000-
7,360,000
3,200,000
18-49 136,938,833 8,900,000 8,050,000-
9,950,000
3,290,000
50-64 63,302,200 8,870,000 7,820,000-
10,300,000
3,810,000
≥65 49,244,195 4,650,000 4,050,000-
5,550,000
2,600,000
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All ages 323,127,513 30,900,000 27,300,000-
35,900,000
14,500,000
Season Estimated illnesses Estimated medical visits
No. 95% CI No. 95% CI
2010-2011 21,100,000 17,600,000-
27,700,000
10,000,000 8,190,000-
13,200,000
2011-2012 9,230,000 7,280,000-
13,800,000
4,300,000 3,390,000-
6,450,000
2012-2013 35,600,000 30,100,000-
44,300,000
16,600,000 14,000,000-
20,800,000
2013-2014 28,400,000 25,000,000-
33,000,000
12,600,000 10,900,000-
14,800,000
2014-2015 34,300,000 30,300,000-
40,100,000
16,200,000 14,100,000-
19,200,000
Approximate
5-season range
(No.)
9,230,000-35,600,000 4,300,000-16,600,000
2015-2016 24,600,000 21,500,000-
28,600,000
11,100,000 9,570,000-
13,100,000
2016-2017 30,900,000 27,300,000-
35,900,000
14,500,000 12,500,000-
17,100,000
Age (yrs) Averted illnesses Averted medical visits
No. 95% CI No. 95% CI
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6 months-4 602,000 160,000-
1,130,000
403,000 107,000-758,000
5-17 1,920,000 1,320,000-
2,700,000
999,000 680,000-
1,400,000
18-49 527,000 32,000-1,010,000 195,000 11,800-371,000
50-64 1,640,000 926,000-
2,380,000
703,000 393,000-
1,040,000
≥65 604,000 0-1,470,000 338,000 0-839,000
All ages 5,290,000 3,910,000-
7,000,000
2,640,000 1,940,000-
3,500,000
Season Averted illnesses Averted medical visits
No. 95% CI No. 95% CI
2010-2011 5,040,000 3,440,000-
7,720,000
2,510,000 1,700,000-
3,890,000
2011-2012 1,980,000 1,160,000-
3,670,000
968,000 556,000-
1,810,000
2012-2013 5,630,00 4,240,000-
8,330,000
2,700,000 2,000,000-
4,090,000
2013-2014 6,680,000 5,040,000-
8,900,000
3,080,000 2,250,000-
4,190,000
2014-2015 1,610,000 610,000-
3,460,000
793,000 296,000-
1,740,000
2015-2016 5,080,000 3,540,000-
7,080,000
2,500,000 1,730,000-
3,530,000
2016-2017 5,290,000 3,910,000-
7,000,000
2,640,000 1,940,000-
3,500,000
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*Estimates from FluVaxView. (10)
†Estimates from US Flu VE Network. (11)
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Figure 1: Estimates of Influenza-associated Illness, Medical Visits, and
Hospitalizations — United States, 2010–2011 to 2016–2017 Influenza
Seasons
Age Vaccine coverage* Vaccine eﬀectiveness †
% 95% CI % 95% CI
6 months-4 years 69.4 68.1-70.7 41 13-60
5-17 years 55.2 54.4-56.0 51 39-61
18-49 years 33.1 32.3-33.9 19 0-34
50-64 years 44.9 43.9-45.9 40 24-53
≥65 years 64.8 63.8-65.8 20 -11-43
Overall 46.8 46.3-47.3 40 32-46
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Figure 2: Schematic Diagram Describing Estimation of Community Illness
and Outpatient Medical Visits Associated Influenza Starting with Crude
Hospitalization Rates From FluSurv-NET — United States, 2016–2017
Influenza Season
1 Reed C, Chaves SS, Daily Kirley P, et al. Estimating influenza disease burden from
population-based surveillance data in the United States. PLoS One 2015;10:e0118369.
2 Reed C, Angulo FJ, Swerdlow DL, et al. Estimates of the prevalence of pandemic (H1N1)
2009, United States, April-July 2009. Emerg Infect Dis 2009;15:2004-7.
3 Biggerstaﬀ M, Jhung M, Kamimoto L, Balluz L, Finelli L. Self-reported influenza-like illness
and receipt of influenza antiviral drugs during the 2009 pandemic, United States, 2009-2010.
Am J Public Health 2012;102:e21-6.
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Questions & Answers
How does CDC estimate the number of hospitalizations, illnesses, and medically-
attended illnesses associated with influenza that occurred in the United States?
Laboratory-confirmed influenza-associated hospitalization rates by age group were obtained
from FluSurv-NET, a collaboration between CDC, the Emerging Infections Program Network,
and selected state and local health departments in 13 geographically distributed areas in the
United States that conduct population-based surveillance. Reported hospitalization rates
were adjusted using a multiplier to correct for underreporting, which is calculated from the
percent of persons hospitalized with respiratory illness who were tested for influenza and the
average sensitivity of influenza tests used in the surveillance hospitals (Figure 2). These
values were measured from data collected during four post-pandemic seasons; data from
two seasons were previously reported (2).
Adjusted rates were applied to the U.S. population by age group to calculate the numbers of
influenza-associated hospitalizations. The numbers of influenza illnesses were then estimated
from hospitalizations based on previously measured ratios that reflect the estimated number
of ill persons per hospitalization in each age group (5).
The numbers of persons seeking medical care for influenza were then calculated using age
group-specific data on the percentages of persons with a respiratory illness who sought
medical care, which were estimated from results of the 2010 Behavioral Risk Factor
Surveillance Survey (12).
All estimates were rounded to three significant digits.
How does CDC estimate the number of influenza-associated outcomes that were
prevented with influenza vaccination?
The annual estimates of influenza vaccination coverage by month during each season and
the final end-of-season vaccine eﬀectiveness measurements were used to estimate how
many persons were not protected by vaccination during the season and thus were at risk for
these outcomes.
The rate of each outcome among persons at risk was then used to estimate the number of
influenza-associated outcomes that would have been expected in the same population if no
one had been protected by vaccination. Finally, the averted outcomes attributable to
vaccination were calculated as the diﬀerence between outcomes in the hypothetical
unvaccinated population and the observed vaccinated population.
Estimates of 2016–2017 influenza vaccination coverage by month from July 2016 through
April 2017, were based on self-report or parental report of vaccination status using data from
the National Immunization Survey for children aged 6 months-17 years and Behavioral Risk
Factor Surveillance Survey data for adults aged ≥18 years (10).
Vaccine eﬀectiveness estimates for the 2016–2017 season were derived from the US
Influenza Vaccine Eﬀectiveness Network, a group of five academic institutions that conduct
annual vaccine eﬀectiveness studies. (11) The network estimates the eﬀectiveness of
vaccination for preventing real-time reverse transcription polymerase chain reaction-positive
influenza among persons with acute respiratory illness of ≤7 days duration seen in hospitals,
emergency departments, or outpatient clinics in communities in four states.
Calculations were stratified by month of the year to account for annual variations in the timing
of disease and vaccination and then summed across the whole season. The prevented
fraction was calculated as the number of averted illnesses divided by the total illnesses that
would have been expected in an unvaccinated population.
All estimates were rounded to three significant digits.
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